October 26, 2007 08:51 ET Issues Correction, October 26, 2007: RHGP Projecting Gross Profits for Fiscal 2007 of $14 Million and Net Income Between $10-$11 Million

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Peter Antipatis of Capital Research Group Inc.

MIAMI, FL--(Marketwire - October 26, 2007) - is issuing a correction to an earlier press release dated October 11, 2007, and October 3, 2007, in which it was incorrectly stated in a Market Harmonics research report that Renhuang Pharmaceuticals, Inc. (OTCBB: RHGP) Fiscal Year 2007 Revenues, "will be approximately $16.5 million, and that net income will be approximately $13.5 million."

The correct figures for Fiscal 2007 are as follows. The company is projecting that gross profits for FY 2007 will be approximately $14 million, and that net income will be between $10-$11 million. Estimates for 2008 are remaining unchanged, as stated by Market Harmonics, "For FY 2008, and since we are expecting a doubling in production levels, we are forecasting gross profits of $25.5 million, and net income of $19.3 million." To view the entire report, please go to apologizes for this mistake, and invites all market participants to visit to get the most up to date and accurate information on all of its client companies.'s Daily Stock Updates:, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed. For more go to

All material herein was prepared by CRG Partners, Inc. (CRGP) based upon information believed to be reliable. The information contained herein is not guaranteed by CRGP to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRGP is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. CRGP has been compensated by third party shareholders with shares or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRGP has been compensated twenty thousand shares for RHGP, and may receive up to twenty thousand shares in future installments. CRGP may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRGP and its web site are operated under a license from Capital Research Group, Inc., Inc. and One Source Solutions Inc. (Licensors) and CRGP is not the agent of any of the Licensors and CRGP is solely responsible for all statements made herein. CRGP's affiliates, officers, directors and employees intend to buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. CRGP will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

Contact Information